Hubertus von Baumbach, Chairman of the Board, Boehringer Ingelheim

The Boehringer Ingelheim group is one of the 20 globally leading pharmaceutical companies, with its base headquarters in Ingelheim, Germany. The company was established in 1885, as a family-owned business, but has grown into a worldwide phenomenon with 175 international affiliates and about 51,000 employees. It’s now a global group of companies having one clear vision: to serve our society by improving healthcare for human beings as well as animals, principally through innovation. They are creating widespread and transformative value in three business areas i.e., human pharmaceuticals, animal healthcare and biopharmaceuticals.

Boehringer Ingelheim is governed by the Board of Managing Directors of five key managerial members; the Chairman of the Board is Mr. Hubertus von Baumbach. They lead innumerable initiatives and activities encompassing scientific research, studies, partnerships, relief or emergency support and public health improvement, through dozens of international offices in popular cities within Asia, Europe, Australasia, North America, South America and Africa!

An International Pioneer within Pharmaceutics and Animal Healthcare

Boehringer Ingelheim is primarily a pharmaceuticals company; in fact, it’s one of the world’s leading providers of the world’s best quality medicine within human pharma, animal pharma and biopharma.

Within human pharma, they offer dozens of patented products in key interest areas: cardiovascular, oncology, respiratory, central nervous system, metabolic diseases, immunology and retinal health.

For animal healthcare, the company works dedicatedly to provide advanced, innovative and preventative and smart healthcare for veterinarians as well as people raising or caring for animals. Thus, they provide patented medicines for common ailments, diseases and concerns for a wide variety of animals including swine, horses, livestock like cattle, poultry or ruminants, pet animals and more.

The group’s biopharma brand ‘Boehringer Ingelheim BioXcellence™’is renowned as a world-leading biopharmaceutical company. Equipped with exhaustive technological capabilities from DNA to product completion, the company can offer tailor-made services to the biopharma industry easily.

Improving Healthcare through Research, Collaborations and Partnerships

The group brings extraordinary efforts for the sake of innovation as well as partnership for better healthcare. “We embrace the power of partnership and diversity of minds across life-science and animal health communities to realize even more innovation and incubate new ideas. By working together, we can learn more, do more and achieve more, and accelerate the development of the next generation of breakthroughs that will improve the health and wellbeing of people and animals now and in generations to come,” Mr. Baumbach states.

The group is dedicated towards bringing breakthrough medicine to improve the lives of human beings as well as animals. It has around 100 ongoing clinical and pre-clinical projects to research ways to develop better medicine today. Their investments are concentrated in areas of significant human healthcare need like cardiometabolic diseases, central nervous system, respiratory diseases, immunological illnesses, cancer immunology and retinal health. Similarly for animal healthcare, the group pours exhaustive efforts to help veterinarians, pet or livestock owners and public healthcare officials to improve animal healthcare measures today as well as the future. Thus far, they have introduced transformative veterinary therapeutics, parasiticides and vaccines into many countries by collaborating with key individuals with the healthcare ecosystem.

Further, the group embraces ‘technology for better healthcare’. They believe that digital and other technologies can bring in better ways to solve some of healthcare’s biggest challenges, rooted in science and innovation. So, the group combines a scientific approach to create better healthcare with innovative technologies to nurture new ideas for better healthcare – all oriented towards challenges of the future, rather than only today.

Laying a Strong Foundation for Better Healthcare in the Future

“Creating breakthrough medicines that change patients’ lives starts with a commitment to identify the health challenges of the future and advance emerging science. As an independent and family-owned company, we have the freedom to pursue our long-term vision, with distinctive approaches that enable new journeys of discovery today that will transform the lives of patients in generations to come,” Mr. Baumbach clarifies.

One of Boehringer Ingelheim’s secrets to success is a crystal clear organizational identity. They have a single purpose: to dedicatedly serve humankind through better human and animal healthcare. They are to people-oriented: they take responsibility to help members of their communities, especially patients. They firmly believe in and practice ‘sustainability’: they are long-term oriented, they plan in terms of generations and they are respectful of the environment. Through investing in science and innovative, they unlock value for healthcare significantly. In sum, they are laying a strong and steady foundation for better healthcare in the future, through a culture that celebrates collaborating for the larger purpose of everyone’s welfare.

Boehringer Ingelheim is strongly established as a modern pioneer within the pharma industry and is actively inspiring better healthcare today.